TY - JOUR
T1 - The Effect of Point Mutations on the Biophysical Properties of an Antimicrobial Peptide
T2 - Development of a Screening Protocol for Peptide Stability Screening
AU - Pohl, Christin Alina
AU - Zalar, Matja
AU - Bialy, Inas El
AU - Indrakumar, Sowmya
AU - Peters, Günther H.J.
AU - Friess, Wolfgang
AU - Golovanov, Alexander P.
AU - Streicher, Werner W.
AU - Noergaard, Allan
AU - Harris, Pernille
PY - 2020
Y1 - 2020
N2 - Therapeutic peptides and proteins show enormous potential in the pharmaceutical market, but high costs in discovery and development are limiting factors so far. Single or multiple point mutations are commonly introduced in protein drugs to increase their binding affinity or selectivity. They can also induce adverse properties, which might be overlooked in a functional screen, such as a decreased colloidal or thermal stability, leading to problems in later stages of the development. In this study, we address the effect of point mutations on the stability of the 4.4 kDa antimicrobial peptide plectasin, as a case study. We combined a systematic high-throughput biophysical screen of the peptide thermal and colloidal stability using dynamic light scattering and differential scanning calorimetry with structure-based methods including small-angle X-ray scattering, analytical ultracentrifugation, and nuclear magnetic resonance spectroscopy. Additionally, we applied molecular dynamics simulations to link obtained protein stability parameters to the protein's molecular structure. Despite their predicted structural similarities, all four plectasin variants showed substantially different behavior in solution. We observed an increasing propensity of plectasin to aggregate at a higher pH, and the introduced mutations influenced the type of aggregation. Our strategy for systematically assessing the stability and aggregation of protein drugs is generally applicable and is of particular relevance, given the increasing number of protein drugs in development.
AB - Therapeutic peptides and proteins show enormous potential in the pharmaceutical market, but high costs in discovery and development are limiting factors so far. Single or multiple point mutations are commonly introduced in protein drugs to increase their binding affinity or selectivity. They can also induce adverse properties, which might be overlooked in a functional screen, such as a decreased colloidal or thermal stability, leading to problems in later stages of the development. In this study, we address the effect of point mutations on the stability of the 4.4 kDa antimicrobial peptide plectasin, as a case study. We combined a systematic high-throughput biophysical screen of the peptide thermal and colloidal stability using dynamic light scattering and differential scanning calorimetry with structure-based methods including small-angle X-ray scattering, analytical ultracentrifugation, and nuclear magnetic resonance spectroscopy. Additionally, we applied molecular dynamics simulations to link obtained protein stability parameters to the protein's molecular structure. Despite their predicted structural similarities, all four plectasin variants showed substantially different behavior in solution. We observed an increasing propensity of plectasin to aggregate at a higher pH, and the introduced mutations influenced the type of aggregation. Our strategy for systematically assessing the stability and aggregation of protein drugs is generally applicable and is of particular relevance, given the increasing number of protein drugs in development.
KW - aggregation assessment
KW - peptide screening
KW - pharmaceutical screening
KW - protein aggregation
KW - protein characterization
KW - protein engineering
KW - protein−protein interactions
U2 - 10.1021/acs.molpharmaceut.0c00406
DO - 10.1021/acs.molpharmaceut.0c00406
M3 - Journal article
C2 - 32609526
AN - SCOPUS:85090507119
SN - 1543-8384
VL - 17
SP - 3298
EP - 3313
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 9
ER -